NKGen Biotech develops natural killer (NK) cell therapies that enhance the immune system's ability to target and eliminate cancerous cells. By restoring immune function, the company addresses the challenge of ineffective cancer treatments that fail to leverage the body's own defenses.
Funding
$2.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many cancer treatments fail to fully leverage the body's own immune system to target and eliminate cancerous cells, leading to ineffective outcomes. Restoring and enhancing the immune system's natural ability to fight cancer remains a significant challenge.
Solution
NKGen Biotech develops natural killer (NK) cell therapies designed to enhance the immune system's ability to recognize and destroy cancer cells. Their approach focuses on restoring immune function, enabling the body to more effectively target and eliminate diseased cells. By leveraging the power of a patient’s own immune system, NKGen aims to improve treatment outcomes. The company's NK cell immunotherapies are designed to maximize immune integrity.
Target Audience
The primary target audience includes patients with cancer and individuals with compromised immune systems, as well as healthcare providers seeking innovative immunotherapeutic options.
Features
- Development of unique natural killer (NK) cell therapies.
- SNK cell therapy for potential benefits in Alzheimer’s.
- Focus on restoring immune function.
- NK cells enhance a patient’s ability to target and eliminate diseased cells.